Last update 21 Nov 2024
Pegylated recombinant human endostatin(Simcere Pharmaceutical Group Ltd.)
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Recombinant protein |
Synonyms |
Target- |
Mechanism Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with Pegylated recombinant human endostatin(Simcere Pharmaceutical Group Ltd.)聚乙二醇化重组人血管内皮抑制素在晚期/转移性非小细胞肺癌或其他实体瘤的安全性、耐受性和药代动力学研究
[Translation] Safety, tolerability and pharmacokinetics of pegylated recombinant human endostatin in patients with advanced/metastatic non-small cell lung cancer or other solid tumors
A Phase Ⅰb Study Evaluating the Safety, Tolerability and Pharmacokinetics of Pegylated Recombinant Human Endostatin (PEG-ENDO) in Subjects With Advanced / Metastatic Non-small Cell Lung Cancer (NSCLC) or Other Solid Tumors
注射用聚乙二醇化重组人血管内皮抑制素在健康志愿者的单中心、开放、单次给药剂量递增的I期临床试验方案
[Translation] A single-center, open-label, single-dose escalation phase I clinical trial protocol for pegylated recombinant human endostatin for injection in healthy volunteers
100 Clinical Results associated with Pegylated recombinant human endostatin(Simcere Pharmaceutical Group Ltd.)
Login to view more data
100 Translational Medicine associated with Pegylated recombinant human endostatin(Simcere Pharmaceutical Group Ltd.)
Login to view more data
100 Patents (Medical) associated with Pegylated recombinant human endostatin(Simcere Pharmaceutical Group Ltd.)
Login to view more data
100 Deals associated with Pegylated recombinant human endostatin(Simcere Pharmaceutical Group Ltd.)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| metastatic non-small cell lung cancer | Phase 1 | CN | 15 Apr 2020 | |
| metastatic non-small cell lung cancer | Phase 1 | CN | 15 Apr 2020 | |
| metastatic non-small cell lung cancer | Phase 1 | CN | 15 Apr 2020 | |
| metastatic non-small cell lung cancer | Phase 1 | CN | 15 Apr 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free